SCHEMBL4342076

SCHEMBL4342076

Cn1ccc(C(=O)CC(=O)O)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.39
MEN1 O00255 2/20 0.39
CYP3A4 P08684 2/20 0.39
HPGD P15428 2/20 0.39
KDM4E B2RXH2 1/20 0.39
MAPT P10636 1/20 0.39
ALOX15 P16050 1/20 0.39
CES1 P23141 1/20 0.39
MAPK1 P28482 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
AKR1B1 P15121 1/20 0.36
PTGDR Q13258 1/20 0.34
ERCC5 P28715 2/20 0.34
FEN1 P39748 2/20 0.34
PTPN1 P18031 1/20 0.34
SLC18A3 Q16572 1/20 0.33
PLOD2 O00469 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7325386 0.81 KMT2A (0.43) KMT2AMEN1CYP3A4HPGDKDM4E
SCHEMBL12094828 0.80 MAPT (0.42) KMT2AMEN1HPGDMAPTMAPK1
SCHEMBL5269154 0.79 ALDH1A1 (0.37) KMT2AMEN1CYP3A4HPGDKDM4E
SCHEMBL7502013 0.78 GSK3B (0.48) PTPN1SLC18A3
SCHEMBL4502421 0.78 ALDH1A1 (0.47) KMT2ACYP3A4HPGDKDM4EMAPT
SCHEMBL20523112 0.78 ALDH1A1 (0.48) KMT2AMEN1HPGDKDM4EMAPT
SCHEMBL369526 0.77
SCHEMBL29941295 0.77 L3MBTL1 (0.50) KMT2AKDM4EMAPTCES1SMN1; SMN2
SCHEMBL14686008 0.76 RAB9A (0.61) HPGDMAPTALOX15MAPK1SMN1; SMN2
Hydrochloric Acid SCHEMBL11715676 0.75 TSHR (0.42) KMT2AMEN1HPGDKDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130078213-A1 THROMBOPOIETIN MIMETICS GLAXOSMITHKLINE LLC 2013-03-28 US disclosed
EP-1889838-B1 Thrombopoietin mimetics SMITHKLINE BEECHAM CORP (US) 2009-10-14 EP disclosed
EP-1889838-A1 Thrombopoietin mimetics SmithKline Beecham Corporation (US) 2008-02-20 EP disclosed
EP-1864981-A1 Thrombopoietin mimetics SmithKline Beecham Corporation (US) 2007-12-12 EP disclosed
US-20070129338-A1 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION 2007-06-07 US disclosed
US-20040019190-A1 Thrombopoietin mimetics NOVARTIS AG (CH) 2004-01-29 US disclosed
EP-1294378-A4 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORP (US) 2004-01-28 EP disclosed
EP-1294378-A2 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2003-03-26 EP disclosed
WO-2001089457-A2 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2001-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070129338-A1 THROMBOPOIETIN MIMETICS MPL, THPO, TEK KMT2A 1838/4885MEN1 229/4885CYP3A4 3534/4885
US-20130078213-A1 THROMBOPOIETIN MIMETICS MPL, THPO, TEK KMT2A 1838/4885MEN1 229/4885CYP3A4 3534/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.